Stock PYPD POLYPID LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News PolyPid Ltd.

Equities

PYPD

IL0011326795

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
4.5 USD +0.22% Intraday chart for PolyPid Ltd. -3.33% +18.42%
May. 08 Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024
May. 08 PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Polypid : Notice of ANNUAL and EXTRAORDINARY General Meeting of shareholders to be held on July 2, 2024 - Form 6-K
PU
POLYPID : AMENDED AND RESTATED 2012 SHARE OPTION PLAN - Form 6-K
PU
Transcript : PolyPid Ltd., Q1 2024 Earnings Call, May 08, 2024
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections
AQ
PolyPid to Participate in Citizens JMP Life Sciences Conference
AQ
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
AQ
PolyPid Ltd. Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections
CI
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
AQ
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
AQ
Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
AQ
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial
CI
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
AQ
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc.
CI
PolyPid Enters Into $16.2 Million Private Placement Deal
MT
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PYPD Stock
  4. News PolyPid Ltd.